Midterm Evaluation of Project: Sickle Cell Disease (SCD) – How an Alzheimer medication might save children’s lives

Evaluation Objectives and Purpose
1. To support the grantee’s reflection on the ways in which the research will contribute to introducing the therapy – if found effective – to regions strongly affected by SCD.

2. Fondation Botnar works with a systemic approach, which assumes that changes does not take place in a linear path, but rather requires a number of different factors to contribute to making the change. The evaluation should support the grantee’s reflection on the research through creating an understanding of the projects long-term critical path and context that influences it. Furthermore, Fondation Botnar wishes to understand how its contribution to the research has made a difference in the field of developing effective treatments for sickle cell disease in low-income regions.

3. To learn about the status of the research, and to assess its fairness and equity
Fondation Botnar support the concept of fair partnerships in research based on the principles and Research Fairness Initiative1 defined by the Swiss Commission for Research Partnerships with Developing Countries (KFPE). It is important for the Foundation that the research it supports is fair and equitable, building lasting partnerships and capacity sustainably. The evaluation should appraise the current status of research fairness in the project for both the foundation as a grant maker and the grantee as a researcher to reflect on and to initiate improvements.

4. To feed into the development of the overall monitoring and evaluation (M&E) and knowledge management system of Fondation Botnar
Fondation Botnar has been developing its strategic learning and evaluation system. The evaluation can contribute to this process by developing indicators and/or guiding questions that could be used in other research projects funded by the Foundation

Downloads


EvalProject_6141_ToR_V2 (PDF 266 kB)

Weitere Auskünfte


Fondation Botnar
David Suhe
E-Mail
T 0041612010479